A regulatory perspective What do I want to know? June M Raine MHRA, - - PowerPoint PPT Presentation

▶
a regulatory perspective
SMART_READER_LITE
LIVE PREVIEW

A regulatory perspective What do I want to know? June M Raine MHRA, - - PowerPoint PPT Presentation

Feb 24, 2024 43 likes •356 views

A regulatory perspective What do I want to know? June M Raine MHRA, UK 11 December 2017 What does regulator want to know? Regulatory decision-making responsibilities Answering the regulatory questions Accessing

slide-1
SLIDE 1

A regulatory perspective

What do I want to know?

June M Raine MHRA, UK 11 December 2017

slide-2
SLIDE 2

2

What does regulator want to know?

Regulatory decision-making responsibilities Answering the regulatory questions Accessing decision-relevant data Moving forward …how can we do better?

slide-3
SLIDE 3

3

Regulatory decision-making responsibilities

I m pact of regulatory action

Signal detection & risk m anagem ent

Lifecycle benefit risk evaluation

slide-4
SLIDE 4

4

Today’s challenge - earlier access to medicines

slide-5
SLIDE 5

5

Santoro et al 2017 Drug safety 40:855-869

slide-6
SLIDE 6

6

Benefit risk in wider clinical use Effectiveness Populations not studied Rare ADRs Long latency ADRs

Uncertainties at time of approval

20 40 60 80 100 120 1 10 100 1000 10000 Frequency of ADR Time to onset of ADR days

slide-7
SLIDE 7

7

Size of clinical database before approval

For 2 0 0 new “standard” medicines median total no patients= 1 7 0 8 For orphan drugs = 4 3 8 patients For 84 medicines for chronic use 7 9 .8 % met guidelines (at least 100 patients for 1Yr)

Duijnhoven et al PLoS March 2013

slide-8
SLIDE 8

8

Important knowledge gaps to be filled

Special populations

pregnancy paediatrics elderly

At risk groups eg immunosuppressed Long term safety

slide-9
SLIDE 9

9

Detecting new safety issues in EU

Simplified reporting of ICSRs to EudraVigilance and re-routing to MS Improved quality and completeness of Individual Case Safety Report data – better searchability & efficiency Enhanced signal detection and data analysis tools to support signal detection by member states & MAHs Better detection of new or changing safety issues enabling rapid action to protect pubic health

slide-10
SLIDE 10

10

Outcomes of signal assessment

PRAC Sep 2012 – Jun 2017

Product Information update [PERCENTAGE] Routine PhVig & monitor in PSUR 36% Ongoing within signal procedure 6% Ongoing within PSUSA/PSUR 1.6% Referral evaluation 4.3% Update of RMP 2.2% PASS 0.5%

slide-11
SLIDE 11

11

11

slide-12
SLIDE 12

12

What do I want to know?

How the medicine is being used What is drug exposure Outcomes of interest Background rates of events of interest What is drug attributable risk Has regulatory action minimised risk When will I get the answers

slide-13
SLIDE 13

13

Answering regulatory questions - RMPs

In the first 5 years after approval, 20.7% of uncertainties identified at approval were resolved

slide-14
SLIDE 14

14

Answering regulatory questions - PASS

British Journal of Clinical Pharmacology Volume 83, Issue 4, 884-893

slide-15
SLIDE 15

15

Answering regulatory questions - RMMs

slide-16
SLIDE 16

16

Accessing decision-relevant data

Database studies

  • Eg risk characterisation, investigation of

targeted AEs, impact of regulatory action

Drug utilisation studies

  • Eg to assess patterns of use, effectiveness
  • f risk minimisation or help plan PASS

Registries (prospective cohorts)

  • Eg assess safety profile, health outcomes

in clinical use, consider comparator

slide-17
SLIDE 17

17

Strengths and limitations of registries

Limitations

  • Substantial set up & running costs
  • Time consuming to initiate
  • Medications commonly missing
  • ADRs not routinely recorded
  • Co-morbidities missing
  • Data ownership/governance
  • Data Quality
  • If no comparator will limit utility
  • Relevant clinical parameters
  • Natural history of disease
  • Standard of care
  • Patient stratification
  • RCTs
  • Open label studies possible
  • Capture off label use
  • Information on high risk groups
  • Patient reported outcomes

Strengths

slide-18
SLIDE 18

18

Patient registries – research ready?

Biologics Haemophilia Pregnancy Multiple Sclerosis Blood and Marrow Transplantation

slide-19
SLIDE 19

19

Examples of some EU regulatory questions

How is Radium 223 used in non- symptomatic or mildly symptomatic metastatic prostate cancer? Are risk minimisation measures to reduce harm of exposure to valproate in pregnancy effective? Is Human Papilloma Virus Vaccine associated with increased risk of fatigue syndromes in adolescent girls?

slide-20
SLIDE 20

20

Understanding how medicine is used

Establishing extent of concomitant use of Radium 223 and abiraterone plus steroids across EU while urgent safety review is taken forward

slide-21
SLIDE 21

21 Maximised SPRT for ME/Chronic Fatigue Syndrome for girls aged 12/13 years (2008-2009)

1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52

Week of Surveillance Log Likelihood Ratio Critical value 10% events reported 25% events reported 50% events reported 75% events reported 100% events reported

ADR reports - observed vs expected analysis

HPV vaccine - chronic fatigue syndrome

slide-22
SLIDE 22

22

HPV vaccine - background rates of CFS

slide-23
SLIDE 23

23

Investigating vaccine signal using RWE

Donegan et al 2013, Vaccine 31, 43, 4961-7

slide-24
SLIDE 24

24

Impact of regulatory action - valproate

Developmental disorders up to 30 -40% of pre-school children exposed in utero in addition to 11% risk of birth defects EU referral in 2014 – strengthened warnings and extensive communications

Meador et al NEJM 2009

slide-25
SLIDE 25

25

Understanding valproate use in member states

slide-26
SLIDE 26

26

Effect of valproate action in UK

5 10 15 20 25 30 35 Jan - Jun 2010 Jul - Dec 2010 Jan - Jun 2011 Jul - Dec 2011 Jan - Jun 2012 Jul - Dec 2012 Jan - Jun 2013 Jul - Dec 2013 Jan - Jun 2014 Jul - Dec 2014 Jan - Jun 2015 Jul - Dec 2015 Jan - Jun 2016 Jul - Dec 2016 Jan - Jun 2017

Rate per 10,000 women

VPA prevalence in females aged 14-45 years

Communications disseminated

slide-27
SLIDE 27

27

Moving forward – how can we do better?

Meaningful evidence Valid evidence Expedited evidence Transparent evidence

Schneeweiss S et al 2016 Clin Ph Ther 100 6 633-46

slide-28
SLIDE 28

28

Generating meaningful evidence

Rassen J at ISoP Liverpool, 2017

slide-29
SLIDE 29

29

Generating timely evidence

Example: Has prescribing of codeine in children changed following regulatory action in 2013?

Common protocol reduces variability due to misaligned definitions, analytical models Makes use of existing regulatory network  Access to high quality electronic health records  Effective allocation of existing resources  Sharing of expertise and data Greater part of EU population in same study Pilot study to gain experience Assessment of data by PRAC in 2018

slide-30
SLIDE 30

30

30

Moving forward – how can we do better?

Agree on common goal – timely access to decision-relevant data to achieve measurable public health outcomes Scenario-specific planning for capability to link local or distributed data sources at global level, support rapid cycle analysis Multi-disciplinary teams including regulators, data providers, pharma and academia to work on common data format

slide-31
SLIDE 31

31

Pharmacovigilance Risk Assessment Committee

Regulators are ready to support!